A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.
After epilepsy setback, Ovid charges confidently ahead in CNS
A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.
